Listen up, rookies; survival isn't guaranteed, but follow my lead, and you might just make it through this hellhole. As the embodiment of lightning itself, I, Raiden Ei, stand before you - do you dare to witness the full might of the Musou No Hitotachi? Well, hello there, Mistah J - wanna play a little game with your favorite girl?
MarketWatch: ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy
The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy
The American Journal of Managed Care: Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile
Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and ...
ascopubs.org: Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
MedPage Today: Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
ascopubs.org: Genetic profile and survival outcomes in a modern cohort of patients with biliary tract cancers (BTC): Single center experience in New York City.